Compare STIM & OKYO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | STIM | OKYO |
|---|---|---|
| Founded | 2003 | 2007 |
| Country | United States | United Kingdom |
| Employees | N/A | N/A |
| Industry | Medical/Dental Instruments | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 105.5M | 85.3M |
| IPO Year | 2018 | 2021 |
| Metric | STIM | OKYO |
|---|---|---|
| Price | $1.48 | $1.60 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 3 |
| Target Price | $3.00 | ★ $6.33 |
| AVG Volume (30 Days) | ★ 1.4M | 193.1K |
| Earning Date | 03-17-2026 | 07-18-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 57.25 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $52,776,000.00 | N/A |
| Revenue This Year | $11.51 | N/A |
| Revenue Next Year | $11.63 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.80 | $1.03 |
| 52 Week High | $5.05 | $3.35 |
| Indicator | STIM | OKYO |
|---|---|---|
| Relative Strength Index (RSI) | 53.04 | 39.86 |
| Support Level | $1.22 | $1.55 |
| Resistance Level | $1.79 | $1.75 |
| Average True Range (ATR) | 0.15 | 0.11 |
| MACD | 0.03 | 0.01 |
| Stochastic Oscillator | 99.40 | 41.38 |
Neuronetics Inc a commercial stage medical technology company focused on designing, developing and marketing products that improve the quality of life for patients who suffer from psychiatric disorders. Its first commercial product, the NeuroStar Advanced Therapy System, is a non-invasive and non-systemic office-based treatment that uses transcranial magnetic stimulations, or TMS, to create a pulsed, MRI-strength magnetic field that induces electrical currents designed to stimulate specific areas of the brain associated with mood. The company designed the NeuroStar Advanced Therapy as a non-invasive therapeutic alternative to treat patients who suffer from MDD and to address many of the key limitations of existing treatment options.
OKYO Pharma Ltd is a biopharmaceutical company. The company is developing therapeutics to improve the lives of patients with inflammatory eye diseases and chronic pain. It offers solutions for various diseases such as Dry Eye Disease, Non-infectious Anterior Uveitis, Allergenic Conjunctivitis, Chronic Pain, and Ocular Pain.